“Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial”, J of Skin, vol. 9, no. 6, p. s607, Nov. 2025, doi: 10.25251/qx64pd52.